Chemotherapy-Induced Nausea and Vomiting Drugs Market Size, Share, and Industry Analysis, By Drug Type (5-HT3 Receptor Antagonists, Neurokinin-1 Receptor Antagonists, Corticosteroids, Cannabinoid Receptor Agonist, and Others), By Application (Prophylaxis and Treatment), By Emetogenicity (Highly emetogenic chemotherapy (HEC), Moderately emetogenic chemotherapy (MEC), and Low/minimal emetogenic chemotherapy), By Route of Administration (Parenteral, Oral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Others), and Regional Forecast 2026-2034

The chemotherapy-induced nausea and vomiting drugs market size was valued at USD 2.60 billion in 2025. The market is projected to grow from USD 2.82 billion in 2026 to USD 5.42 billion by 2034, exhibiting a CAGR of 8.45% during the forecast period.

The chemotherapy-induced nausea and vomiting drugs market is poised for significant growth over the forecast period. The market is driven by the increasing prevalence of cancer and the growing demand for supportive care for chemotherapy patients. The patients must be kept stable, hydrated, and compliant with planned chemotherapy cycles for better outcomes. As more cancer patients receive these regimens, providers increasingly rely on guideline-based prophylaxis to prevent acute and delayed CINV and avoid unplanned dose delays. Key companies operating in the market are focusing on improving real-world control by simplifying dosing in outpatient infusion workflows and expanding access through strategic collaborations for licensing, distribution, and portfolio transactions that strengthen regional reach.

• For instance, in February 2026, Helsinn Healthcare SA collaborated with MagnaPharm, a leading pharmaceutical group operating in Europe, for long-term Licensing, Distribution and Supply of AKYNZEO (combination of netupitant-palonosetron) and ALOXI (palonosetron) in Poland, Romania, the Czech Republic, Slovakia, and Hungary. Both products are indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients. Such developments boost market growth.

Furthermore, funding initiatives, research and development, expanding pipeline portfolios, and new product launches by major companies strengthen their market position and support the overall market growth.

Chemotherapy-Induced Nausea and Vomiting Drugs Market Driver

Rising Cancer Prevalence And Expanding Chemotherapy Volumes Drive Market Growth

Rising cancer prevalence is one of the predominant factors driving the demand for chemotherapy-induced nausea and vomiting drugs. As the number of patients starting systemic chemotherapy increases, the population exposed to emetogenic regimens that trigger CINV also rises. Oncology providers face higher downstream costs if these nauseas /vomiting are left unmanaged, resulting in extra nurse calls, unplanned clinic visits, dehydration-related ER use, and even dose delays. To prevent such incidents, they tighten protocol-based prophylaxis to keep treatment, creating a steady and recurring demand for combination regimens used in high-risk and moderate-risk chemotherapy. Higher chemo throughput in outpatient infusion centers also drives the adoption of simplified, reliable antiemetic options that reduce chair-time variability and help standardize care.

• For instance, in October 2025, Helsinn reported MyRisk trial results showing AKYNZEO improved the prevention of chemotherapy-induced nausea and vomiting versus standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors.

Download Free sample to learn more about this report.

For instance, in 2025, the National Cancer Institute estimated that 2,041,910 new cancer cases would occur. The increasing prevalence of cancer is driving demand for chemotherapy-induced nausea and vomiting drugs in cancer treatment regimens.

Chemotherapy-Induced Nausea and Vomiting Drugs Market Restraint

Adverse Effects and Tolerability Issues Reducing Adherence to Multi-Drug Regimens, Hampering Market Growth

Adverse effects and tolerability issues are among the leading factors hampering the growth of the CINV market. oncologists are more cautious about how aggressively they layer multi-drug prophylaxis. When patients experience side effects such as sedation, constipation, infusion reactions, or injection-site issues, adherence drops, which leads clinicians to either de-intensify regimens or switch to lower-risk alternatives; these factors can also result in slower uptake and hamper growth potential.

• For instance, in October 2021, Supportive Care in Cancer published an article titled 'Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy‑induced nausea and vomiting: a network meta‑analysis' that reported adverse effects/tolerability can limit uptake. It also noted that the safety trade-off mattered—the higher dose was associated with more sedation, reducing patient willingness to continue, and making clinicians cautious about routine use in all patients.

Chemotherapy-Induced Nausea and Vomiting Drugs Market Opportunity

Expanding Antiemetic R&D Pipelines and Lifecycle Innovation to Create Lucrative Growth Opportunity

A key factor offering significant growth opportunities for the market is the expanding antiemetic R&D pipelines and lifecycle innovation. Current CINV management experiences some challenges, especially for delayed nausea and for patients who struggle with multi-day dosing. Many companies continue to invest in new formulations and differentiated delivery to improve consistency and convenience, thereby bridging these gaps in patient care. As pipelines expand, providers get more alternatives that better fit outpatient infusion workflows. These factors collectively lead to greater protocol adoption, higher utilization per chemotherapy cycle, and a stronger value mix toward differentiated products rather than commoditized generics, facilitating faster market expansion.

• For instance, in October 2025, Aphios Corporation received an NIH grant to advance Zindol, a ginger-derived botanical drug candidate being developed for chemotherapy-induced nausea and vomiting (CINV).

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Cancer, By Key Regions, 2025
• Pipeline Analysis, By Key Players
• Key Industry Developments (Strategic Partnerships, Collaborations, Acquisitions, and Mergers)
• Reimbursement Scenario by Key Countries/Regions
• New Product Launches, By Key Players

Analysis by Drug Type

Based on the drug type, the global chemotherapy-induced nausea and vomiting drugs market is segmented into 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoid receptor agonists, and others.

Among these, the 5-HT3 receptor antagonist segment is estimated to hold a leading share. 5-HT3 drugs tend to dominate as they are the foundation of most antiemetic protocols across HEC, MEC, and even lower-risk regimens. As chemotherapy volumes rise, hospitals standardize pre-chemo order sets, and 5-HT3 agents remain the most consistently used component in those sets. This creates repeat, high-frequency use across cycles, even when other add-on drugs change by risk level. Their broad applicability also means they show up in both inpatient and outpatient pathways, supporting sustained demand. Underscoring these factors, key companies are participating in strategic collaborations and acquisitions to expand their offerings in the segment.  

• For instance, in January 2022, Cumberland Pharmaceuticals acquired SANCUSO (granisetron transdermal system, a 5-HT3 antagonist) to expand its oncology supportive care portfolio. Such developments are expected to lead to segmental growth.

Analysis by Application

Based on application, the global chemotherapy-induced nausea and vomiting drugs market is segmented into prophylaxis and treatment.

Among these, the prophylaxis segment is anticipated to hold a leading market share. The high share is attributed to the segment; as healthcare providers focus more on preventing CINV than on treating it after symptoms start. Uncontrolled CINV can trigger dehydration, unplanned visits, and dose delays, leading healthcare providers to focus more on prevention. As centers aim to protect chemo adherence and patient experience, they increasingly follow guideline-style preventive regimens as part of standard care pathways. Highlighting these factors, key companies are increasing research and development initiatives and launching new products to expand their offerings in the segment. 

• For instance, in October 2025, Helsinn highlighted positive AKYNZEO results versus standard of care in patients receiving moderately emetogenic chemotherapy (MEC) with additional risk factors, reinforcing the focus on preventive control.

Analysis by Emetogenicity  

Based on emetogenicity, the global chemotherapy-induced nausea and vomiting drugs market is segmented into Highly emetogenic chemotherapy (HEC), Moderately emetogenic chemotherapy (MEC), and Low/minimal emetogenic chemotherapy.

Moderately emetogenic chemotherapy (MEC) accounted for a leading market share. As a large portion of real-world chemotherapy use falls into the moderate-risk bucket, which still requires planned antiemetic coverage, the segment is dominated by this use. As more patients receive outpatient chemotherapy, providers standardize prophylaxis for MEC to reduce avoidable complications and improve completion of treatment cycles. This creates a steady patient pool that repeatedly consumes CINV drugs across multiple cycles. Additionally, new products launched in the segment reinforce growth.  

• For instance, in November 2025, Shilpa Medicare announced positive Phase 3 topline results for OERIS (ondansetron extended-release injection) studied in patients receiving moderately or highly emetogenic chemotherapy, supporting product development targeted to these risk groups. Such developments are expected to drive the segmental growth.

Analysis by Route of Administration

In terms of route of administration, the global chemotherapy-induced nausea and vomiting drugs market is segmented into parenteral, oral, and others.

The parenteral segment is anticipated to account for the largest share. Parenteral often dominates value as many high-impact CINV regimens are delivered as first-line treatment in infusion settings due to their rapid onset. IV administration improves compliance and workflow predictability in inpatient settings. This supports higher uptake of injectable branded products versus purely oral approaches and their critical commercial importance.

• For instance, in May 2025, Heron Therapeutics announced a settlement related to CINVANTI (aprepitant) injectable emulsion, underscoring the ongoing commercial importance of injectable CINV products. Such developments are expected to drive the segmental growth.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies & drug stores, and others.

Hospital pharmacies are expected to dominate the market. CINV prevention is typically embedded into chemotherapy administration pathways, and hospitals/infusion centers procure the core antiemetics. As protocols become more standardized and purchasing consolidates within hospital systems, hospital channel volume strengthens. Even when oral follow-on doses are used, the initial regimen is often chosen in the hospital setting. Furthermore, strategic collaboration among these hospital pharmacies drives growth in the segment.   

• For instance, in August 2023, Techdow USA and CTTQ Pharma announced a collaboration agreement and launch of Fosaprepitant for Injection (an NK1 pathway antiemetic used in CINV prevention), with CTTQ manufacturing and Techdow commercializing under the Techdow USA label.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 42.0 % of the global chemotherapy-induced nausea and vomiting drugs market in 2025. The strong growth in North America is driven by the rising prevalence of cancer and the growing demand for supportive care drugs. Expanding pipelines and growing research and development in the region are among the principal factors driving global dominance. Emphasizing these factors, key companies are also advancing their offerings through strategic partnerships and boosting market growth.

• For instance, in October 2024, Heron Therapeutics reaffirmed the availability and ample supply of CINVANTI and SUSTOL as alternatives in the event of a potential IV fluid shortage, underscoring the importance of reliable CINV prevention products in U.S. care pathways. Such developments drive the market growth in the region.

Europe is expected to grow at a significant CAGR during the forecast period. The oncology systems in the region are increasingly embedding CINV prevention into formal treatment pathways to protect quality of life and reduce avoidable utilization. As more countries emphasize consistent supportive care standards, hospitals and specialty partners expand access to established CINV brands and ensure stable distribution across major markets. This drives broader uptake of prophylaxis regimens, resulting in repeat utilization tied directly to chemotherapy cycles. Additionally, favorable government regulations and strategic partnerships expand distribution and access, reducing option friction and boosting market growth.

• For example, in January 2025, Helsinn and ESTEVE announced the renewal of their distribution and license agreement to commercialize AKYNZEO and ALOXI in Germany, reinforcing continued investment in CINV supportive care coverage in a key European market and thereby fueling market growth.

Asia Pacific is expected to grow at a stable CAGR during the forecast period. The region's growth is driven by expanding oncology capacity and greater access to chemotherapy. The increasing demand for modern supportive care, particularly solutions that improve adherence outside the hospital, supports the market growth in the region. As more treatment shifts to high-throughput centers, there is a stronger pull for options that simplify dosing and improve real-world control across multi-day regimens. Partnerships that localize manufacturing and commercialization also help broaden availability, accelerating the adoption of preventive antiemetics across large patient populations.

• For instance, in January 2026, Solasia Pharma announced a license agreement with MAAB for Sancuso rights in China, aimed at restructuring/strengthening the commercial framework and improving access. Such developments are driving the region's growth.

Key Players covered

The global chemotherapy-induced nausea and vomiting drugs market is consolidated, with a few players capturing a significant market share.

The report includes the profiles of the following key players.

• Merck & Co., Inc. (U.S.)
• Heron Therapeutics, Inc. (U.S.)
• Helsinn Healthcare SA (Switzerland)
• Cumberland Pharmaceuticals Inc. (U.S.)
• Genentech, Inc. (U.S.)
• Novartis AG (Switzerland)
• Bausch Health Companies Inc. (Canada)
• Benuvia Manufacturing, LLC (U.S.)

Key Industry Developments

• November 2025: Shilpa Medicare Limited completed its complex clinical program SMLINJ011, with positive topline Phase 3 results for Shilpa's OERIS (Ondansetron Extended-Release Injection)—a formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV).
• January 2023: Glenmark Pharmaceuticals Ltd. launched a unique I.V. injection formulation, AKYNZEO I.V., in India for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn.